11/27/2023 0 Comments Lights out 2 david crawfordThese are small molecules and peptides, so they're not really taken orally very well, they're broken down that led to the injections. But he did note that if you had something that was potent, and you gave it in super physiologic doses, that you could actually just beat the pituitary down so it didn't release the LH and then also FSH, after a couple of days. Schally developed this but could never get an antagonist, something that really would shut down the axis. Estrogens work at the brain level to pretend it's testosterone. And then when the testosterone gets to a certain point, it feeds back on the pituitary area and shuts it down. It's a pretty simple mechanism the pituitary releases LHRH, that hits the testicle, that results in the rise in testosterone and some other things. So to play around with a couple of the amino acid sequences, and trying to do an antagonist that, when you get it, would shut down the messenger from the pituitary to the testes to produce testosterone. Decapeptide means 10 amino acids, so that's not a big molecule. He analyzed and described the decapeptide and began work on a way to antagonize this decapeptide. He won a Nobel Prize for his work in studying the messengers from the pituitary, particularly the LHRH pathways. Estrogen was a pill, and it really worked well except for the side effects, which included cardiovascular side effects and also issues with breast enlargement.įast forward to the 1970s and the work of Andrew Schally, MD, from New Orleans. Plus, there were side effects-hot flashes and things like that. The problem with bilateral orchiectomy was that we were removing the testicles, and doing that wasn't exactly a hit with a lot of men. Later, Huggins won a Nobel Prize for that. Actually, the first oral therapy for any cancer was estrogen back in the 1940s. Hodges, MD, started working with removing men's testicles and giving estrogen as a pill. The history of androgen deprivation therapy-what we used to call hormone therapy-really goes back to the 1940s. Crawford is a professor of urology at the University of California, San Diego.Ĭould you provide an overview of the development of injectable LHRH analogs? David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. Urology Times® is celebrating its 50th anniversary in 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |